Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.

China’s 3SBio, in a joint venture with CPE Funds, seeks to buy Canadian CDMO Therapure Biomanufacturing for $290 million pending shareholder approval.

Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.

India-based Alembic Pharmaceuticals is selling its formulation manufacturing plant in Baddi to Scott Edil Pharmacia for an undisclosed amount.

Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.

WuXi's small molecule CDMO STA is adding a drug development services operation as it builds itself into an end-to-end CDMO.

It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.

Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.

Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.